Trials / Completed
CompletedNCT02062294
An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients
Retrospective Review of Valganciclovir Efficacy in Preventing CMV Disease in D+/R- Liver Transplant Recipients - A Non-Interventional Program
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 14 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This retrospective review will evaluate the efficacy of Valcyte (valganciclovir) in preventing Cytomegalovirus (CMV) disease in D+/R- liver transplant recipients. Data from eligible patients will be collected for the 6 months following transplantation.
Conditions
Timeline
- Start date
- 2010-07-31
- Primary completion
- 2011-09-30
- Completion
- 2011-09-30
- First posted
- 2014-02-13
- Last updated
- 2017-07-05
- Results posted
- 2016-02-11
Locations
3 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT02062294. Inclusion in this directory is not an endorsement.